gave them autism; This serious case was reported by a consumer and described the occurrence of autism in a patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included infliximab for product used for unknown indication. On an unknown date, the patient received Shingrix and infliximab. On an unknown date, an unknown time after receiving Shingrix, the patient experienced autism (Verbatim: gave them autism) (serious criteria GSK medically significant). The action taken with infliximab was unknown. The outcome of the autism was resolved. It was unknown if the reporter considered the autism to be related to Shingrix. The company considered the autism to be unrelated to Shingrix. Additional Information: GSK Receipt Date: 17-JAN-2025 The reporter reported that the patient got Shingrix when they started infliximab and it gave them autism. On an unknown date, an unknown time after receiving infliximab, the patient experienced autism. It was unknown if the reporter considered the autism to be related to infliximab. This case has been linked to the US2025AMR010349 case reported by the same reporter.; Sender’s Comments: Autism spectrum disorder is an unlisted event which is considered unrelated to GSK vaccine Shingrix. US-GSK-US2025AMR010349:same reporter